Jun Hye Seo

Jun Hye Seo

Auto-generated profile, based on publicly available information

Jun Hye Seo

Division of Nephrology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YLYongseop Lee
Yongseop Lee
JSJun Hye Seo
Jun Hye Seo
JSJaeeun Seong
Jaeeun Seong
SASangmin Ahn
Sangmin Ahn
MHMin Han
Min Han
NKNam Su Ku
Nam Su Ku
Lee Y, et al. J Korean Med Sci. 2024 Aug;39:e276. https://doi.org/10.3346/jkms.2024.39.e276

1 September 2025 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
JLJin Hyeog Lee
Jin Hyeog Lee
JSJun Hye Seo
Jun Hye Seo
TKTai Yeon Koo
Tai Yeon Koo
Jang-Hee ChoJang-Hee Cho
Jang-Hee Cho
KKKyung Pyo Kang
Kyung Pyo Kang
JYJaeseok Yang
Jaeseok Yang
Background: Patients with sensitization and blood type O experience increased waiting times for deceased-donor kidney transplantation (DDKT). While allocation benefits are needed to resolve inequity in DDKT opportunity, whether DDKT has comparable outcomes in this disadvantaged population requires further study. This study assessed these outcomes and developed a new allocation system that balances equity and utility.Methods: Patients from national and hospital cohorts from two centers in Korea were categorized as B1 to B4 (according to panel reactive antibody [PRA] positivity and ABO blood type) and A1 to A4 (based on the maximal PRA% and blood type), respectively. Competing risk and Cox regression analyses were performed to assess the effects of PRA and blood type on graft failure and mortality, respectively. Based on DDKT opportunities and posttransplant outcomes, a new scoring system for kidney allocation was developed.Results: The national and hospital cohorts included 3,311 and 819 patients, respectively, who underwent DDKT. Despite the disparities in DDKT opportunities, the graft failure rates and mortality did not differ among the different PRA and blood type groups. Furthermore, posttransplantation outcomes did not differ according to the categories with different DDKT opportunities. A new scoring system to provide additional points to disadvantaged populations was developed based on the hazard ratios for DDKT.Conclusion: A new allocation approach based on PRA and ABO blood types offers benefits to disadvantaged patients with fewer DDKT opportunities and could enhance equity without sacrificing utility in Korea, which has a long waiting time for DDKT.

1 January 2025 in Infection & Chemotherapy
Verified
Journal Article
Open access
JKJongheon Kim
Jongheon Kim
YLYongseop Lee
Yongseop Lee
JSJun Hye Seo
Jun Hye Seo
JSJaeeun Seong
Jaeeun Seong
JLJung Ah Lee
Jung Ah Lee
JYJoon-Sup Yeom
Joon-Sup Yeom
Kim J, et al. Infect Chemother. 2025 Jul;57:e42. https://doi.org/10.3947/ic.2025.0048